The Role of PI3K Inhibition in Lymphoid Malignancies

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial

(2019) Loretta J Nastoupil et al.   Lancet Haematology

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

(2019) Ian W. Flinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma

(2018) Tycel J. Phillips et al.   BLOOD

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

(2018) Howard A Burris et al.   LANCET ONCOLOGY

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

(2018) Angelo Di Leo et al.   LANCET ONCOLOGY

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper

(2018) Antonio Cuneo et al.   HEMATOLOGICAL ONCOLOGY

Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

(2018) Jacob Drobnyk Soumerai et al.   JOURNAL OF CLINICAL ONCOLOGY

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

(2018) Ian W. Flinn et al.   BLOOD

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study

(2018) Matthew S Davids et al.   Lancet Haematology

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

(2017) Anas Younes et al.   HAEMATOLOGICA

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

(2017) Martin Dreyling et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-Hodgkin lymphoma

(2017) James O Armitage et al.   LANCET

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) José Baselga et al.   LANCET ONCOLOGY

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

(2017) Anas Younes et al.   HAEMATOLOGICA

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials

(2017) Sonali M Smith et al.   Lancet Haematology

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

(2016) A. Patnaik et al.   ANNALS OF ONCOLOGY

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

(2016) P. M. Barr et al.   BLOOD

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies

(2016) Changchun Deng et al.   BLOOD

Idelalisib in the management of lymphoma

(2016) C. Y. Cheah et al.   BLOOD

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

Erratum: Corrigendum: PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

The landscape of new drugs in lymphoma

(2016) Anas Younes et al.   Nature Reviews Clinical Oncology

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma

(2015) C. Y. Cheah et al.   BLOOD

Management of adverse events associated with idelalisib treatment: expert panel opinion

(2015) Steven E. Coutré et al.   LEUKEMIA & LYMPHOMA

The Wnt5a-Ror2 axis promotes the signaling circuit between interleukin-12 and interferon-γ in colitis

(2015) Akira Sato et al.   Scientific Reports

How I treat the peripheral T-cell lymphomas

(2014) A. J. Moskowitz et al.   BLOOD

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

(2014) Khaled Ali et al.   NATURE

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

(2013) D. Tan et al.   BLOOD

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

(2013) Ningshu Liu et al.   MOLECULAR CANCER THERAPEUTICS

Targeting pathological B cell receptor signalling in lymphoid malignancies

(2013) Ryan M. Young et al.   NATURE REVIEWS DRUG DISCOVERY

Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor

(2012) Patrizia Nanni et al.   PLoS One

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

(2011) J. Hoellenriegel et al.   BLOOD

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

PI3 Kinase Signals BCR-Dependent Mature B Cell Survival

(2009) Lakshmi Srinivasan et al.   CELL

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY